G1 Therapeutics (GTHX) Appoints Jacks Lee to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
G1 Therapeutics Announces Addition of Jacks Lee to Board of Directors
June 28, 2022 7:30 AM EDTRESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Mr. Lee has developed extensive experience in manufacturing and supply chain management in the life sciences industry. Mr. Lee currently serves as Senior Vice President Manufacturing & Supply of Merck & Co., Inc., a global premier research-intensive biopharmaceutical health care company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products.
... More